Calcium alpha-ketoglutarate (Ca-AKG)
Analytical
Code: 253150
Calcium alpha‑ketoglutarate (Ca‑AKG) — dietary supplement salt of AKG; studied for aging biology and bone metabolism; typical research dose around 1 g/day (SR).
Calcium alpha-ketoglutarate (Ca-AKG) ≥98% purity is a calcium salt of alpha‑ketoglutarate (AKG), a TCA‑cycle metabolite studied for aging biology and bone metabolism. It is a white to off‑white powder suitable for dietary supplement use.
| Benefit | Typical study dose* | Key human findings | High-quality sources |
|---|---|---|---|
| Healthy aging biomarkers | ~1 g/day (SR) for 6–8 months | Uncontrolled Rejuvant® user study reported ~8‑year reduction in DNA‑methylation age; exploratory and not placebo‑controlled. | PMC |
| Frailty/healthspan (animal) | Dietary Ca‑AKG in middle‑aged mice | Extended lifespan, reduced frailty scores, ↓ inflammatory cytokines (e.g., IL‑6). | Cell Metab |
| Bone metabolism | 6 g/day for 6 months (postmenopausal) | Lowered bone resorption marker (CTX); BMD change small/non‑significant over 6 months. | PubMed |
| Exercise/muscle | Varies by salt (AKG blends) | Human data mixed and often with other AKG salts (e.g., arginine‑AKG); translate cautiously. | MDPI |
*Doses shown are typical in studies; products and formulations differ. Pending RCT (“ABLE”) is testing 1 g/day sustained‑release for 6 months.
Mechanistic highlights
- Energy/epigenetic co‑factor: AKG participates in the TCA cycle and acts as a co‑substrate for dioxygenases (TET/Jumonji), potentially shaping epigenetic programs linked to aging.
- Inflammation tone: Murine data show ↓ pro‑inflammatory cytokines (e.g., IL‑6), aligning with improved frailty scores.
- Bone biology: In aged models, AKG supports osteogenesis and limits bone loss via epigenetic effects.
Safety & practical use
- Usual supplemental range: 0.5–2 g/day; sustained‑release 1 g/day is under RCT evaluation.
- Tolerability: Small studies report good short‑term tolerability (e.g., 4.5 g/day in dialysis; 6 g/day in women) with metabolic benefits reported.
- Drug status: Dietary supplement, not an approved drug for disease treatment; human outcome benefits remain unproven pending RCTs.
- Medical oversight: Avoid in pregnancy/breastfeeding due to limited data; consult a clinician for kidney disease, calcium disorders, or interacting meds.
- white to off-white powder
- Room (25-40C)
- 24 Months from manufacturing or testing date.
- 500mg - 2000mg
- 1000mg
- 500mg - 2000mg
- 1000mg
- Powder mixing for food/beverage (oil‑phase disperse or glycol premix)
- Heat Tolerant
- 0.00 - 0.00
- -
| Test Name | Specification |
|---|---|
| Appearance | White to off-white powder |
| Purity | ≥98% |
| Calcium (Ca2+, on dried basis) | 18–21% |
| Water | ≤7.0% |
| pH (6.0–8.0) | 6.0–8.0 |
| Loss on drying | ≤1.0% |
| Lead (Pb) | ≤0.1 ppm |
| Mercury (Hg) | ≤0.1 ppm |
| Cadmium (Cd) | ≤0.2 ppm |
| Arsenic (As) | ≤0.1 ppm |
| Total microbial count | ≤500 CFU/g |
| Coliform | ≤0.92 MPN/g |
| Mold and yeast | <50 CFU/g |
| Staphylococcus aureus | 0/25 g |
| Salmonella | 0/25 g |
Cart
No products
Subtotal:
0.00
Total
0.00
THB
Loading Researcher Network details...